An Open Phase I Single Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
Latest Information Update: 26 Dec 2024
Price :
$35 *
At a glance
- Drugs BI 2536 (Primary)
- Indications Anaplastic large cell lymphoma; B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 04 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2012 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov.
- 28 Jul 2006 New trial record.